EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Luisa Schwarzmüller iD, Janina Müller, Efstathios-Iason Vlachavas iD, Lukas Beumers, Lena Fleischhacker iD, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann iD

Molecular Oncology · 2026-11 · 20 (11) · 2764-2783

DOI: 10.1002/1878-0261.70286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 05.06.2026. Verfasst von Luisa Schwarzmüller und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: p21-Activated Kinases, Tamoxifen, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most frequent malignancy and the second leading cause of cancer‐related mortality in women. Estrogen receptor‐positive (ER+) tumors are treated with endocrine therapies such as tamoxifen or aromatase inhibitors (AI), aimed at disrupting estrogen signaling. While these therapies are initially effective, resident tumor cells can develop resistance, leading to relapse. The p21‐activated kinase 1 (PAK1), a regulator of oncogenic signaling pathways, has been implicated in tamoxifen resistance. However, it remains unclear whether PAK1 also affects the response to other endocrine therapies. Here we show PAK1 activity was elevated in tamoxifen‐resistant and long‐term estrogen‐deprived MCF7 cell lines and showed enhanced responsiveness to EGF stimulation. Inhibition of PAK1 effectively reduced cell proliferation in both models, with distinct effects on PAK1 downstream substrates. In the tamoxifen resistance context, PAK1 inhibition induced activation of the pro‐apoptotic protein BAD and triggered apoptosis while proliferation‐related kinases were suppressed in the estrogen‐deprived model. Our findings position PAK1 as a mediator of resistance to endocrine therapies suggesting that targeting PAK1 may present a novel strategy to overcome endocrine therapy resistance in ER+ breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

p21-Activated KinasesTamoxifenBreast NeoplasmsDrug Resistance, NeoplasmAromatase InhibitorsHumansFemaleMCF-7 CellsCell ProliferationApoptosisCell Line, TumorEnzyme Activation

Stichwörter der Autor:innen

ER‐positive breast cancerPAK1endocrine therapy resistancephosphoproteomics

Substanzen

p21-Activated KinasesTamoxifenAromatase InhibitorsPAK1 protein, human

Autor:innen und Institutionen

  • Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
  • Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Luisa Schwarzmüller, Efstathios-Iason Vlachavas, Lena Fleischhacker, Stefan Wiemann

Zitieren

APA

Schwarzmüller, L., Müller, J., Vlachavas, E. I., Beumers, L., Fleischhacker, L., Burmester, S., Wörner, A., Karolus, S., Helm, D., Körner, C., & Wiemann, S. (2026). PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model. Molecular Oncology, 20(11), 2764-2783. https://doi.org/10.1002/1878-0261.70286

Vancouver

Schwarzmüller L, Müller J, Vlachavas EI, Beumers L, Fleischhacker L, Burmester S, et al. PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model. Molecular Oncology. 2026;20(11):2764-2783. doi:10.1002/1878-0261.70286

BibTeX
@article{Schwarzmller2026,
  author = {Schwarzmüller, Luisa and Müller, Janina and Vlachavas, Efstathios-Iason and Beumers, Lukas and Fleischhacker, Lena and Burmester, Sara and Wörner, Angelika and Karolus, Sabine and Helm, Dominic and Körner, Cindy and Wiemann, Stefan},
  title = {PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2764--2783},
  doi = {10.1002/1878-0261.70286}
}
Kostenlos starten →